Replies to post #171426 on Cytodyn Inc (CYDY)

[ClosetInvestor]

“Can’t afford that downtime while chasing Covid critical.”

Keyword here is chasing. There was a time when leronlimab was leading the pack for COVID severe/critical, but 15 months later, we wait AGAIN for protocol approval.

“At minimum, keep Recknor.”

He has yet to prove himself, but I agree, if he is valuable, keep him. Rahman was the new man on the block, touted by NP as the savior. Recknor is the new Rahman and he too could step down at anytime just like Rahman did.

[name]

Whole 13d group will do nothing benefit to CYDY but depressing the SP.